Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.3148
- Book/Share 19.2598
- PB 4.3787
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.186
- MktCap 210363031600.0
- FreeCF/Share 6.7803
- PFCF 12.346
- PE 12.9005
- Debt/Assets 0.3027
- DivYield 0.038
- ROE 0.3591
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.
Read More
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
Read More
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Neutral
I reiterate my buy rating on Merck, citing its attractive valuation and improving technicals despite sector headwinds. Merck's recent earnings beat was driven by strong oncology and cardiovascular portfolios, offsetting Gardasil weakness and Keytruda patent concerns. The stock offers a solid 4% dividend yield, low PEG ratio, and consistent growth, making it appealing for income and value investors.
Read More
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Read More
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Read More
Why Merck (MRK) is a Top Value Stock for the Long-Term
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
4 Solid Dividend Stocks to Buy On The Cheap
Published: August 05, 2025 by: 24/7 Wall Street
Sentiment: Positive
These 4 dividend stocks have generated steady passive income for investors for many years.
Read More
Income Strategy: I'm Buying 2 Elite Mispriced Dividends
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Positive
In the current tech-heavy market, I explore two compelling value stocks with strong yields and trade at deep discounts to historical valuations. Both have competitive advantages and strong histories of capital returns to shareholders. Both appear to be severely mispriced, offering enterprising investors the opportunity to capture value before the market pendulum swings back.
Read More
5 Regular Payout High-Yield VIG Dividends to Outpace the Fed
Published: July 30, 2025 by: 24/7 Wall Street
Sentiment: Positive
These VIG dividend stocks have high yields and regular payouts. Their yields outpace the Federal Reserve's long-term target.
Read More
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
Read More
Merck Stock Is Almost A Classical Benjamin Graham Investment
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
Merck is good value for money. It is a highly profitable company. It fulfills almost all of Benjamin Graham's stock-picking criteria.
Read More
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.
Read More
'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify
Published: July 29, 2025 by: CNBC Television
Sentiment: Negative
The Investment Committee debate some of their stocks on the move lower.
Read More
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.
Read More
Here's What Key Metrics Tell Us About Merck (MRK) Q2 Earnings
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Merck will lay off employees and shed some real estate to cut $3 billion in costs
Published: July 29, 2025 by: Market Watch
Sentiment: Negative
Merck's stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.
Read More
Merck posts Q2 earnings miss, unveils cost-cutting initiative
Published: July 29, 2025 by: Proactive Investors
Sentiment: Negative
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares moved lower in early trade as the pharmaceutical company reported second quarter earnings that fell short of estimates. Revenue for the quarter came in at $15.8 billion, down 2% year-over-year and below consensus expectations of approximately $15.75 billion.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
Read More
Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.
Read More
Merck Announces Fourth-Quarter 2025 Dividend
Published: July 22, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Fourth-Quarter 2025 Dividend.
Read More
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages over manual MQC, with automation, regulatory benefits, and a $10B addressable market opportunity. Merck partnership is a key catalyst, enabling global distribution, supply chain optimization, and improved gross margins for Rapid Micro Biosystems.
Read More
Does This Move Make Merck Stock a Buy?
Published: July 20, 2025 by: The Motley Fool
Sentiment: Neutral
Merck (MRK -1.91%), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its famous cancer medicine.
Read More
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
Published: July 20, 2025 by: The Motley Fool
Sentiment: Positive
One of the big reasons to like Pfizer (PFE -0.47%) today is its huge 7.1% dividend yield. To put that yield into context, the S&P 500 index is yielding roughly 1.3% and the average healthcare stock a bit over 1.7%.
Read More
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: July 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options
Read More
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000